Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
AIMS: Aortic valve stenosis (AS) and its precursor, aortic valve sclerosis (ASc), occur frequently in Western populations. Investigations to retard the progression of AS using statins have been unsuccessful. Development of ASc in humans is associated with increased aortic valve backscatter (AVBS) and poor tissue nitric oxide (NO) responsiveness. In an animal model, ramipril retarded AS/ASc development. We have now set out to identify factors associated with the progression of ASc in humans. METHODS AND RESULTS: At baseline and after 4 years, 204 randomly selected subjects (age 63 ± 6 years at study entry) underwent echocardiography with the determination of AVBS values, measurements of platelet NO responsiveness, plasma asymmetric dimethylarginine concentrations, lipid profile, high-sensitivity-C-reactive protein, routine biochemistry, and 25-hydroxy-vitamin D levels. During the study period, 68% of subjects had detectable AVBS progression. On multivariate analysis, higher calcium concentrations (β = 0.22; P = 0.004), poor platelet NO responsiveness (β = 0.18; P = 0.018), and increased arterial stiffness (β = 0.15; P = 0.044) were independent predictors of disease progression. The use of angiotensin-converting enzyme-inhibitors/angiotensin II receptor blockers (ACE-I/ARB) predicted the lack of disease progression (assessed categorically) in the overall cohort and in those without ASc at baseline (n = 159) (β = 0.8; P = 0.025 and β = 1.3; P = 0.001, respectively). No conventional coronary risk factors were associated with disease progression. CONCLUSION: This study of early aortic valve disease (i) demonstrates that disease progression occurs in the majority of the normal ageing population over a 4-year period; (ii) provides evidence of the importance of the NO signalling cascade in disease development and progression; and (iii) provides additional data linking ACE-I/ARB use with the retardation of ASc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iung, B. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00201-x · Cited by 3,530 · cited 1×
“Aortic valve stenosis (AS) is now the most common valve disease in the Western world and its prevalence and incidence are rising.(1,2) In general, AS reflects a progressive increase in calcium deposition within the aortic valve, leading to increased stiffness and progressive narrowing of the valve.”
BackgroundClinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 1×
“despite a far lower prevalence of advanced AS among such populations.(2,4,5)”
BackgroundIntensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Freeman, R. V., & Otto, C. M. (2005) · Circulation · doi:10.1161/circulationaha.104.486738 · Cited by 1,006
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815
Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies
Förstermann, U. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1211 · Cited by 576
Statistic Notes: Regression towards the mean
Bland, J. M., & Altman, D. G. (1994) · BMJ · doi:10.1136/bmj.308.6942.1499 · Cited by 547
New Insights Into the Progression of Aortic Stenosis: Implications for Secondary Prevention
Palta, S., Pai, A. M., Gill, K. S., & Pai, R. G. (2000) · Circulation · doi:10.1161/01.cir.101.21.2497 · Cited by 319
Cited by
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281
The Prevalence, Incidence, Progression, and Risks of Aortic Valve Sclerosis
Coffey, S., Cox, B., & Williams, M. J. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.018 · Cited by 255
Danielsen, R., Aspelund, T., Harris, T. B., & Gudnason, V. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.053 · Cited by 168
“There are also some indications that the renin-angiotensin system and endothelial dysfunction may also be involved in the calcification process of the aortic valve [27, 28].”
BackgroundAging of the Nitric Oxide System: Are We as Old as Our NO?
Sverdlov, A. L., Ngo, D. T. M., Chan, W. P. A., Chirkov, Y. Y., & Horowitz, J. D. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000973 · Cited by 97
Self-citationImpact of hypertension and renin–angiotensin system inhibitors in aortic stenosis
Capoulade, R., Clavel, M., Mathieu, P., Côté, N., Dumesnil, J. G., Arsenault, M., Bédard, É., & Pibarot, P. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12169 · Cited by 97
Metadata
- Authors
- Sverdlov, A. L., Ngo, D. T. M., Chan, W. P. A., Chirkov, Y. Y., Gersh, B. J., McNeil, J. J., & Horowitz, J. D.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-06
- Volume
- 33
- Issue
- 19
- Pages
- 2419-2425
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2147500593
- Cited by
- 35
- References
- 9
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. https://app.cochat.ai/papers/10.1093/eurheartj/ehs171
- The paper
- Sverdlov, A. L., Ngo, D. T. M., Chan, W. P. A., Chirkov, Y. Y., Gersh, B. J., McNeil, J. J., & Horowitz, J. D. (2012). Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics. European Heart Journal. https://doi.org/10.1093/eurheartj/ehs171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.